MedDataX Logo

Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia

NCT ID: NCT01940198

Last Updated: 2013-09-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

117 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-04-30

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study will aim to determine long-term atazanavir experience in a high HIV caseload primary care practice in Sydney, Australia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This observational study will aim to determine long term atazanavir experience in HIV-1 infected patients in a primary care setting.

3\. OBJECTIVES OF THE STUDY i. Primary objective Long-term (2 years or greater) atazanavir experience in HIV-1 infected patients in a primary care setting through retrospective data collection.

ii. Secondary objectives

1. To illustrate long term therapeutic efficacy of atazanavir in ART naïve and experienced HIV-1 infected patients.
2. To illustrate long term tolerability to atazanavir in ART naïve and experienced HIV-1 infected patients.
3. To identify ART treatment history in ART naïve and experienced HIV-1 infected patients on ATV.
4. To identify contraindicated therapy in ART naïve and experienced HIV-1 infected patients on ATV.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Atazanavir long-term primary care setting sydney

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. HIV-1 positive
2. Have commenced ATV between 2002-2008 (Baseline)
3. Follow-up data (clinical and laboratory) available from baseline

Exclusion Criteria

1. Patients not commenced ATV between 2002-2008
2. No follow-up data (clinical and laboratory) available from baseline
3. Patient 'lost to follow-up' with \< 2 years of follow-up data (Clinical and laboratory)
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bristol-Myers Squibb

INDUSTRY

Sponsor Role collaborator

Holdsworth House Medical Practice

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Mark Bloch

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mark Bloch, Dr.

Role: PRINCIPAL_INVESTIGATOR

Holdsworth House Medical Practice

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Holdsworth House Medical Practice

Sydney, New South Wales, Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AI424-417 ST

Identifier Type: -

Identifier Source: org_study_id